Table 2.
Characteristics of patients with CNS progression
| Age (years)/gender | Primary site | Type of breast lymphoma | Tumor size (cm) | IPI | Primary treatment | CNS prophylaxis | Primary response | PFS [months] | Relapsed site | Salvage therapy | ASCT | Survival from relapse [months] | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| #1 | 53F | Rt. breast | PBL | 4.5 | L | CHOP3 + IFRT | None | CR | 25.5 | CNS | WBI, HD-MTX | Yes | 115.3+ |
| #2 | 49F |
Lt. breast, Lt. axial LN, Mediastinal LN |
LSBL | 10.0 | L | R-CHOP4 | None | CR | 29.3 | CNS | WBI | Yes | 14.3 |
| #3 | 53F | Lt. breast | PBL | 3.0 | L | R-CHOP5 | None | PD | 3.5 | CNS | WBI, HD-MTX+Ara-C | No | 70.6 |
| #4 | 41F | Bil. Breast, Lt. axial LN | PBL | 3.0 | L | CHOP4 + IFRT | None | CR | 16.1 | CNS, BM, PB | HD MTX | No | 13.8 |
IPI International Prognostic Index, PFS progression-free survival, ASCT autologous stem cell transplantation, Rt. right, Lt. left, Bil. bilateral, PBL primary breast lymphoma, LSBL limited secondary breast lymphoma, L low risk, CR complete remission, LN lymph node, PD progressive disease, CNS central nervous system, BM bone marrow, PB peripheral blood, WBI whole brain irradiation, HD-MTX high dose methotrexate, NA not applicable, ML malignant lymphoma, Ara-C cytarabine